CardioMol Ltd. is a spin-off of Micar Innovation (Micar21), a drug discovery factory. CardioMol Ltd. is established with the aim of developing a treatment for cardiovascular diseases, including comorbidities and conditions with increased severity in cardiovascular disease patients such as the disease caused by the SARS-CoV-2, the virus behind the COVID-19 infection, the pandemy of 2020.
Micar Innovation (Micar21) Ltd, the CardioMol mother company, has won recognition and acknowledgement for its innovation capacity; in 2018 it was awarded in the start-up category of the ‘Innovative Enterprise of the Year’ ...
Re-purposing of proprietary small molecules for the treatment of COVID19. CardiOVID19 is intended to repurpose our first in class molecules in CCR5/CCR7 antagonists and SLC6A5 proprietary inhibitors and optimize our new ACE2 allosteric binders for the treatment of all patients affected by COVID-19 and other related coronaviruses.
CardiOVID19 is designed to: // - repurpose our proprietary dual acting CCR5/7 antagonists and SLC6A5 inhibitors // - optimize by the aforementioned approaches new ACE2 allosteric ligands, and // - further develop them as treatment for COVID-19 //